Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more
Neuren Pharmaceuticals Limited (NURPF) - Net Assets
Latest net assets as of June 2025: $323.27 Million USD
Based on the latest financial reports, Neuren Pharmaceuticals Limited (NURPF) has net assets worth $323.27 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($331.25 Million) and total liabilities ($7.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $323.27 Million |
| % of Total Assets | 97.59% |
| Annual Growth Rate | 20.48% |
| 5-Year Change | 1403.74% |
| 10-Year Change | 2426.76% |
| Growth Volatility | 135.63 |
Neuren Pharmaceuticals Limited - Net Assets Trend (2004–2024)
This chart illustrates how Neuren Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neuren Pharmaceuticals Limited (2004–2024)
The table below shows the annual net assets of Neuren Pharmaceuticals Limited from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $363.90 Million | +77.34% |
| 2023-12-31 | $205.21 Million | +393.42% |
| 2022-12-31 | $41.59 Million | +5.95% |
| 2021-12-31 | $39.25 Million | +62.20% |
| 2020-12-31 | $24.20 Million | +74.77% |
| 2019-12-31 | $13.85 Million | -43.87% |
| 2018-12-31 | $24.67 Million | +50.75% |
| 2017-12-31 | $16.36 Million | +291.20% |
| 2016-12-31 | $4.18 Million | -70.96% |
| 2015-12-31 | $14.40 Million | -24.51% |
| 2014-12-31 | $19.08 Million | -21.67% |
| 2013-12-31 | $24.36 Million | +284.13% |
| 2012-12-31 | $6.34 Million | -32.93% |
| 2011-12-31 | $9.45 Million | +167.52% |
| 2010-12-31 | $3.53 Million | -51.91% |
| 2009-12-31 | $7.35 Million | +31.86% |
| 2008-12-31 | $5.57 Million | -26.20% |
| 2007-12-31 | $7.55 Million | -53.24% |
| 2006-12-31 | $16.15 Million | -49.79% |
| 2005-12-31 | $32.16 Million | +266.86% |
| 2004-12-31 | $8.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuren Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19122479730.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $180.43 Million | 49.58% |
| Common Stock | $165.27 Million | 45.42% |
| Other Comprehensive Income | $18.20 Million | 5.00% |
| Total Equity | $363.90 Million | 100.00% |
Neuren Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Neuren Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aditya Birla Real Estate Limited
NSE:ABREL
|
$819.68 Million |
|
Hongta Securities Co Ltd
SHG:601236
|
$820.01 Million |
|
Tansun Technology Co Ltd
SHE:300872
|
$820.05 Million |
|
Viad Corp
NYSE:VVI
|
$820.17 Million |
|
Shanghai Emperor of Cleaning Hi-Tech Co Ltd
SHG:603200
|
$819.39 Million |
|
Event Hospitality & Entertainment Limited
F:AQHE
|
$818.59 Million |
|
Jiangsu Yinhe Electronics Co Ltd
SHE:002519
|
$818.39 Million |
|
Jiangsu Shentong Valve Co Ltd
SHE:002438
|
$818.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuren Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 205,207,000 to 363,904,000, a change of 158,697,000 (77.3%).
- Net income of 142,043,000 contributed positively to equity growth.
- Share repurchases of 10,426,000 reduced equity.
- New share issuances of 1,660,000 increased equity.
- Other comprehensive income increased equity by 24,511,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $142.04 Million | +39.03% |
| Share Repurchases | $10.43 Million | -2.87% |
| Share Issuances | $1.66 Million | +0.46% |
| Other Comprehensive Income | $24.51 Million | +6.74% |
| Other Changes | $909.00K | +0.25% |
| Total Change | $- | 77.34% |
Book Value vs Market Value Analysis
This analysis compares Neuren Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.76x to 2.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $0.71 | $7.63 | x |
| 2005-12-31 | $1.61 | $7.63 | x |
| 2006-12-31 | $1.31 | $7.63 | x |
| 2007-12-31 | $0.61 | $7.63 | x |
| 2008-12-31 | $0.45 | $7.63 | x |
| 2009-12-31 | $0.50 | $7.63 | x |
| 2010-12-31 | $0.17 | $7.63 | x |
| 2011-12-31 | $0.25 | $7.63 | x |
| 2012-12-31 | $0.11 | $7.63 | x |
| 2013-12-31 | $0.39 | $7.63 | x |
| 2014-12-31 | $0.25 | $7.63 | x |
| 2015-12-31 | $0.17 | $7.63 | x |
| 2016-12-31 | $0.99 | $7.63 | x |
| 2017-12-31 | $0.18 | $7.63 | x |
| 2018-12-31 | $0.25 | $7.63 | x |
| 2019-12-31 | $0.14 | $7.63 | x |
| 2020-12-31 | $0.23 | $7.63 | x |
| 2021-12-31 | $0.33 | $7.63 | x |
| 2022-12-31 | $0.32 | $7.63 | x |
| 2023-12-31 | $1.57 | $7.63 | x |
| 2024-12-31 | $2.78 | $7.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuren Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 39.03%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 65.51%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.13x
- Recent ROE (39.03%) is above the historical average (-63.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -65.18% | -406.79% | 0.11x | 1.48x | $-6.57 Million |
| 2005 | -41.78% | -1933.70% | 0.01x | 1.77x | $-10.30 Million |
| 2006 | -62.65% | -5848.46% | 0.01x | 1.21x | $-11.73 Million |
| 2007 | -160.95% | -1287.13% | 0.06x | 1.93x | $-12.91 Million |
| 2008 | -276.70% | -677.97% | 0.27x | 1.53x | $-15.98 Million |
| 2009 | 1.33% | 1.99% | 0.49x | 1.37x | $-649.43K |
| 2010 | -136.92% | -105.28% | 0.81x | 1.60x | $-5.25 Million |
| 2011 | -48.96% | 0.00% | 0.00x | 1.17x | $-5.60 Million |
| 2012 | -78.56% | 0.00% | 0.00x | 1.31x | $-5.74 Million |
| 2013 | -46.01% | -235.69% | 0.18x | 1.08x | $-13.75 Million |
| 2014 | -42.99% | -283.08% | 0.13x | 1.15x | $-10.23 Million |
| 2015 | -93.02% | -800.78% | 0.10x | 1.17x | $-14.84 Million |
| 2016 | -287.21% | -381.40% | 0.51x | 1.48x | $-12.43 Million |
| 2017 | 20.09% | 521.08% | 0.04x | 1.10x | $1.65 Million |
| 2018 | 12.46% | 21.97% | 0.53x | 1.08x | $606.10K |
| 2019 | -78.11% | -2185.05% | 0.03x | 1.04x | $-12.20 Million |
| 2020 | -37.99% | -1282.15% | 0.03x | 1.03x | $-11.61 Million |
| 2021 | -19.86% | -243.79% | 0.08x | 1.02x | $-11.72 Million |
| 2022 | 0.44% | 1.26% | 0.34x | 1.04x | $-3.97 Million |
| 2023 | 76.55% | 67.73% | 0.94x | 1.21x | $136.56 Million |
| 2024 | 39.03% | 65.51% | 0.53x | 1.13x | $105.65 Million |
Industry Comparison
This section compares Neuren Pharmaceuticals Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuren Pharmaceuticals Limited (NURPF) | $323.27 Million | -65.18% | 0.02x | $819.58 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |